论文部分内容阅读
目的探讨晚期非小细胞肺癌(NSCLC)中p53蛋白表达与化疗疗效的相关性。方法收集1995年-2011年SCI收录期刊发表的有关p53蛋白与晚期非小细胞肺癌化疗疗效的文献,将研究方法相似的文献归类整理,原始数据汇总后进行Meta分析和统计处理。结果入选10项研究654例患者,p53阳性、阴性各327例;p53阳性患者化疗有效98例(30.0%),p53阴性患者化疗有效132例(40.4%);合并OR为0.70,95%CI(0.38-1.29),P=0.26。结论 p53蛋白阴性NSCLC患者可能比p53阳性患者对化疗的疗效更好,但就目前的研究结果在统计学上尚不能证实显著优于p53阳性患者。
Objective To investigate the relationship between the expression of p53 protein and the curative effect of chemotherapy in advanced non-small cell lung cancer (NSCLC). Methods The literature on the efficacy of chemotherapy for p53 protein and advanced non-small cell lung cancer (NSCLC) published in SCI journals collected from 1995 to 2011 was collected. The documents with similar research methods were collated. The original data were collected and analyzed by meta-analysis and statistical analysis. Results A total of 654 patients were enrolled in the 10 studies, of which p53 was positive and negative, with 327 cases in each. P53 positive patients were treated with chemotherapy (98%) and chemotherapy with p53 negative patients (132 cases, 40.4%). The combined OR was 0.70 and 95% CI 0.38-1.29), P = 0.26. Conclusions Patients with p53 protein-negative NSCLC may have a better response to chemotherapy than p53-positive patients, but the current findings are not statistically significantly superior to p53-positive patients.